keyword
MENU ▼
Read by QxMD icon Read
search

ribose lung cancer

keyword
https://www.readbyqxmd.com/read/29928326/miltirone-induced-apoptosis-in-cisplatin-resistant-lung-cancer-cells-through-upregulation-of-p53-signaling-pathways
#1
Zhongcheng Zhu
The active ingredients of natural plants are important sources of antitumor agents. Miltirone is a major effective ingredient in traditional Chinese medicine and it is considered to have anti-infection and immunosuppressive activities. Clinically, it is often used for the treatment of arthritis and immune diseases. The effect of miltirone on cisplatin-resistant lung cancer cells has not been investigated to date. The present study aimed to examine the anticancer effect of miltirone in cisplatin-resistant lung cancer cells...
June 2018: Oncology Letters
https://www.readbyqxmd.com/read/29922432/cyclooxygenase-inhibitors-combined-with-deuterium-enriched-water-augment-cytotoxicity-in-a549-lung-cancer-cell-line-via-activation-of-apoptosis-and-mapk-pathways
#2
Abdolreza Hassanzade, Ali Mandegary, Elham Sharif, Rokhsana Rasooli, Reza Mohammadnejad, Yaser Masoumi-Ardekani
Objectives: Combination chemotherapy is a rational strategy to increase patient response and tolerability and to decrease adverse effects and drug resistance. Recently, the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to be associated with reduction in occurrence of a variety of cancers including lung cancer. On the other hand, growing evidences suggest that deuterium-enriched water (DEW, D2O) and deuterium-depleted water (DDW) play a role both in treatment and prevention of cancers...
May 2018: Iranian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29906251/randomized-double-blind-phase-ii-study-of-temozolomide-in-combination-with-either-veliparib-or-placebo-in-patients-with-relapsed-sensitive-or-refractory-small-cell-lung-cancer
#3
M Catherine Pietanza, Saiama N Waqar, Lee M Krug, Afshin Dowlati, Christine L Hann, Alberto Chiappori, Taofeek K Owonikoko, Kaitlin M Woo, Robert J Cardnell, Junya Fujimoto, Lihong Long, Lixia Diao, Jing Wang, Yevgeniva Bensman, Brenda Hurtado, Patricia de Groot, Erik P Sulman, Ignacio I Wistuba, Alice Chen, Martin Fleisher, John V Heymach, Mark G Kris, Charles M Rudin, Lauren Averett Byers
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m2 /day, days 1 to 5, of a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent...
June 15, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29849794/tetrandrine-suppresses-lung-cancer-growth-and-induces-apoptosis-potentially-via-the-vegf-hif-1%C3%AE-icam-1-signaling-pathway
#4
Zhuo Chen, Liang Zhao, Feng Zhao, Guanghai Yang, Jian Jun Wang
The present study investigated the effect of tetrandrine on lung cancer cell growth and apoptosis, and its possible underlying molecular mechanism. A549 human lung cancer cells were incubated with between 2.5 and 10 µM tetrandrine for 12, 24 and 48 h, following which the effect of tetrandrine on cell viability and apoptosis were assessed using an MTT assay and flow cytometry. ELISA and western blotting were used to analyze VEGF activity, and the expression of poly (ADP-ribose) polymerase (PARP), phosphorylated protein kinase B (Akt), Bcl-2-associated X protein (Bax), hypoxia inducible factor (HIF)-1α and inter-cellular adhesion molecule-1 (ICAM-1)...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29844165/the-glycerol-backbone-of-phospholipids-derives-from-noncarbohydrate-precursors-in-starved-lung-cancer-cells
#5
Katharina Leithner, Alexander Triebl, Martin Trötzmüller, Barbara Hinteregger, Petra Leko, Beatrix I Wieser, Gabriele Grasmann, Alexandra L Bertsch, Thomas Züllig, Elvira Stacher, Alessandro Valli, Ruth Prassl, Andrea Olschewski, Adrian L Harris, Harald C Köfeler, Horst Olschewski, Andelko Hrzenjak
Cancer cells are reprogrammed to consume large amounts of glucose to support anabolic biosynthetic pathways. However, blood perfusion and consequently the supply with glucose are frequently inadequate in solid cancers. PEPCK-M ( PCK2 ), the mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK), has been shown by us and others to be functionally expressed and to mediate gluconeogenesis, the reverse pathway of glycolysis, in different cancer cells. Serine and ribose synthesis have been identified as downstream pathways fed by PEPCK in cancer cells...
May 29, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29805515/pseudo-ginsenoside-rh2-induces-a549-cells-apoptosis-via-the-ras-raf-erk-p53-pathway
#6
Yuchen Wang, Huali Xu, Zeyuan Lu, Xiaofeng Yu, Chen Lv, Yuan Tian, Dayun Sui
Ginsenoside Rh2, a major effective constituent of ginseng, has been suggested to have a pro-apoptotic effect in a variety of cancer cells. Pseudo-Ginsenside-Rh2 (pseudo-G-Rh2) is a novel derivative of ginsenoside Rh2. The aim of the present study was to evaluate the effect of pseudo-G-Rh2 on the apoptosis of lung adenocarcinoma A549 cells. The cytotoxicity of pseudo-G-Rh2 on A549 cells was evaluated using an MTT assay. Apoptosis was detected using DAPI staining and flow cytometry. The expression of apoptosis associated proteins was identified by western blot analysis...
June 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29800742/bioactivity-based-analysis-and-chemical-characterization-of-cytotoxic-constituents-from-chaga-mushroom-inonotus-obliquus-that-induce-apoptosis-in-human-lung-adenocarcinoma-cells
#7
Jiwon Baek, Hyun-Soo Roh, Kwan-Hyuck Baek, Seulah Lee, Seul Lee, Seong-Soo Song, Ki Hyun Kim
ETHNOPHARMACOLOGICAL RELEVANCE: Inonotus obliquus, also known as Chaga mushroom, is one of the most widely appreciated wild edible mushrooms in Russia and northern European countries and is renowned for its use in cancer treatment. Indeed, recently published in vitro and in vivo studies have demonstrated its anticancer activity in various types of cancer and support its potential application for therapeutic intervention in cancer. However, its activity against lung cancer, the most commonly diagnosed cancer and the leading cause of cancer death worldwide, and the underlying molecular basis of its action remain to be fully elucidated...
May 22, 2018: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/29772677/lambertianic-acid-sensitizes-non-small-cell-lung-cancers-to-trail-induced-apoptosis-via-inhibition-of-xiap-nf-%C3%AE%C2%BAb-and-activation-of-caspases-and-death-receptor-4
#8
Deok Soo Ahn, Hyo Jung Lee, Jisung Hwang, Hyukgyu Han, Bonglee Kim, BumSang Shim, Sung-Hoon Kim
Lambertianic acid (LA) is a biologically active compound from the leaves of Pinus koraiensis. In the present study, apoptotic mechanisms of LA plus TNF-related apoptosis-inducing ligand (TRAIL) were elucidated in non-small cell lung cancer cells (NSCLCs). Cytotoxicity assay, flow cytometry, immunoprecipitation, and Western blotting were performed. Here, combined treatment of LA and TRAIL increased cytotoxicity, sub-G1 population, cleaved poly (ADP-ribose) polymerase (PARP), and caspase3/8/9 in A549 and H1299 cells compared to LA or TRAIL alone...
May 16, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29762727/development-of-targeted-therapy-and-immunotherapy-for-treatment-of-small-cell-lung-cancer
#9
Motonobu Saito, Kouya Shiraishi, Akiteru Goto, Hiroyuki Suzuki, Takashi Kohno, Koji Kono
Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene aberrations has not been adapted yet in small cell lung cancer (SCLC). This is because driver genes and druggable aberrations are rarely identified by next generation sequencing in SCLC...
May 14, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29746926/fucoidan-upregulates-tlr4-chop-mediated-caspase-3-and-parp-activation-to-enhance-cisplatin-induced-cytotoxicity-in-human-lung-cancer-cells
#10
Hsien-Yeh Hsu, Tung-Yi Lin, Chun-Hao Hu, David Ta Fu Shu, Mei-Kuang Lu
Cisplatin-based therapy is a traditional, clinical treatment for cancers, including lung cancer. In this study, we found that sequential therapy, i.e., cisplatin followed by fucoidan, reduced tumor volume in an LLC1-bearing C57BL/6 mouse model. Using a series of combined therapeutic experiments, we found that the inhibition rate of the sequential treatment (cisplatin→fucoidan) was 50 ∼ 75%. However, the inhibition rate of the sequential treatment, with fucoidan pretreatment, was increased to 75 ∼ 85%...
May 7, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29724012/frondoside-a-enhances-the-anti-cancer-effects-of-oxaliplatin-and-5-fluorouracil-on-colon-cancer-cells
#11
Samir Attoub, Kholoud Arafat, Tamam Khalaf, Shahrazad Sulaiman, Rabah Iratni
Over recent years, we have demonstrated that Frondoside A, a triterpenoid glycoside isolated from an Atlantic sea cucumber, has potent in vitro and in vivo anti-cancer effects against human pancreatic, breast, and lung cancer. We have also demonstrated that Frondoside A is able to potentiate and/or synergize the anti-cancer effects of major classical cytotoxic agents, namely, gemcitabine, paclitaxel, and cisplatin, in the treatment of pancreatic, breast, and lung cancer, respectively. This study evaluates the impact of Frondoside A alone and in combination with the standard cytotoxic drugs oxaliplatin and 5-fluorouracil (5-FU) in the treatment of colon cancer using three human colon cancer cell lines, namely, HT-29, HCT-116, and HCT8/S11...
May 1, 2018: Nutrients
https://www.readbyqxmd.com/read/29717133/kinesin-light-chain-4-depletion-induces-apoptosis-of-radioresistant-cancer-cells-by-mitochondrial-dysfunction-via-calcium-ion-influx
#12
Jeong-Hwa Baek, Janet Lee, Hong Shik Yun, Chang-Woo Lee, Jie-Young Song, Hong-Duck Um, Jong Kuk Park, In-Chul Park, Jae-Sung Kim, Eun Ho Kim, Sang-Gu Hwang
Kinesins act as molecular microtubule-dependent motor proteins and have various important cellular functions related to cell division, intracellular transport, and membrane trafficking. However, the function of kinesin light chain 4 (KLC4) in cancer, especially radioresistance, has not been previously described. Thus, we investigated KLC4 function in lung cancer cells and radioresistant R-H460 cells by analyzing alterations in radiosensitivity after gene knockdown with siRNA and by evaluating cellular phenotypes and xenograft tumor growth...
May 2, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29702091/inhibition-of-malat1-sensitizes-liver-cancer-cells-to-5-flurouracil-by-regulating-apoptosis-through-ikk%C3%AE-nf-%C3%AE%C2%BAb-pathway
#13
De-Gang Ji, Lian-Yue Guan, Xiao Luo, Feng Ma, Bin Yang, Hong-Yu Liu
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is involved in tumor cell growth process. However, its role and molecular mechanism in liver cancer is still not fully understood. In this study, we found that MALAT1 was significantly expressed in liver cancer cell lines. And knockdown of MALAT1 suppressed proliferation, migration and invasion of HepG2 cells, accompanied with decrease of Rho-associated coiled-coil-forming protein kinase 1 (ROCK1), α-smooth muscle actin (α-SMA), N-cadherin, Vimentin and TWIST...
June 18, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29651367/-lazarus-response-to-olaparib-in-a-virtually-chemonaive-breast-cancer-patient-carrying-gross-brca2-gene-deletion
#14
Vladimir M Moiseyenko, Vyacheslav A Chubenko, Fedor V Moiseyenko, Lyudmila A Zagorskaya, Yuliya A Zaytseva, Nataliya E Gesha, Evgeny N Zykov, Valeriya I Ni, Elena V Preobrazhenskaya, Anna P Sokolenko, Evgeny N Imyanitov
This report describes an estrogen receptor-positive breast cancer patient, who relapsed at two and a half years after the completion of adjuvant chemotherapy while being on the aromatase inhibition. Based on the clinical evidence for potential sensitivity of the tumor to hormone ablation, everolimus was added to continuing exemestane treatment. Oral chemotherapy was administered at further disease progression, however, it lasted only for 10 days due to rapidly deteriorating condition of the patient. BRCA test was performed just before the failure of endocrine therapy and revealed a gross deletion within BRCA2 gene...
February 4, 2018: Curēus
https://www.readbyqxmd.com/read/29604436/investigational-chemotherapy-and-novel-pharmacokinetic-mechanisms-for-the-treatment-of-breast-cancer-brain-metastases
#15
REVIEW
Neal Shah, Afroz S Mohammad, Pushkar Saralkar, Samuel A Sprowls, Schuyler D Vickers, Devin John, Rachel M Tallman, Brandon P Lucke-Wold, Katherine E Jarrell, Mark Pinti, Richard L Nolan, Paul R Lockman
In women, breast cancer is the most common cancer diagnosis and second most common cause of cancer death. More than half of breast cancer patients will develop metastases to the bone, liver, lung, or brain. Breast cancer brain metastases (BCBM) confers a poor prognosis, as current therapeutic options of surgery, radiation, and chemotherapy rarely significantly extend life and are considered palliative. Within the realm of chemotherapy, the last decade has seen an explosion of novel chemotherapeutics involving targeting agents and unique dosage forms...
March 28, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29584673/effects-of-the-combination-of-gliotoxin-and-adriamycin-on-the-adriamycin-resistant-non-small-cell-lung-cancer-a549-cell-line
#16
Le Van Manh Hung, Yeon Woo Song, Somi Kim Cho
Acquired drug resistance constitutes an enormous hurdle in cancer treatment, and the search for effective compounds against resistant cancer is still advancing. Marine organisms are a promising natural resource for the discovery and development of anticancer agents. In this study, we examined whether gliotoxin (GTX), a secondary metabolite isolated from marine-derived Aspergillus fumigatus , inhibits the growth of adriamycin (ADR)-resistant non-small-cell lung cancer (NSCLC) cell lines A549/ADR. We investigated the effects of GTX on A549/ADR cell viability with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the induction of apoptosis in A549/ADR cells treated with GTX via fluorescence-activated cell sorting analysis, Hoechst staining, annexin V/propidium iodide staining, tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining, and western blotting...
March 27, 2018: Marine Drugs
https://www.readbyqxmd.com/read/29570891/poly-adp-ribose-polymerase-1-as-a-potential-therapeutic-target-in-merkel-cell-carcinoma
#17
Renata Ferrarotto, Robert Cardnell, Shirley Su, Lixia Diao, A Karina Eterovic, Victor Prieto, William H Morrisson, Jing Wang, Merrill S Kies, Bonnie S Glisson, Lauren Averett Byers, Diana Bell
BACKGROUND: Patients with metastatic Merkel cell carcinoma are treated similarly to small cell lung cancer (SCLC). Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC. Our study explores PARP as a therapeutic target in Merkel cell carcinoma. METHODS: We evaluated PARP1 expression and Merkel cell polyomavirus (MCPyV) in 19 patients with Merkel cell carcinoma. Target exome-sequencing was performed in 14 samples...
March 23, 2018: Head & Neck
https://www.readbyqxmd.com/read/29545967/egfr-tyrosine-kinase-inhibitor-hs-10182-increases-radiation-sensitivity-in-non-small-cell-lung-cancers-with-egfr-t790m-mutation
#18
Yang Chen, Youyou Wang, Lujun Zhao, Ping Wang, Jifeng Sun, Rudi Bao, Chenghai Li, Ningbo Liu
Objective: To investigate the potential of HS-10182, a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), as a radiosensitizer in non-small cell lung cancer (NSCLC). Methods: Two cell lines of NSCLCs, A549 that possesses wild-type (WT) EGFRs and H1975 that possesses EGFR L858R/T790M double mutations, were treated with HS-10182 at various concentrations, and cell viabilities were determined using the MTS assay. The cells were tested by clonogenic survival assays to identify the radiosensitivity of both groups...
February 2018: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/29541201/mir-145-suppresses-the-proliferation-invasion-and-migration-of-nsclc-cells-by-regulating-the-bax-bcl-2-ratio-and-the-caspase-3-cascade
#19
Yi Pan, Conglin Ye, Qingshan Tian, Songxin Yan, Xiaoping Zeng, Chu Xiao, Lingyun Wang, Hongmei Wang
Although microRNA (miR)-145 has been identified to be a tumor suppressor in various types of tumor, it promotes the progression of non-small cell lung cancer (NSCLC). However, the precise underlying molecular mechanism of its action remains unclear. The present study investigated the effects of miR-145 on the proliferation, invasion, metastasis and apoptosis of the NSCLC A549 cell line and the underlying molecular mechanism of its action. In vitro cell proliferation, invasion, migration and apoptosis assays were employed, and the expression levels of matrix metalloproteinase (MMP)-2, MMP-9, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3and poly(ADP-ribose) polymerase (PARP) were evaluated by western blot analysis...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29524123/bci-induces-apoptosis-via-generation-of-reactive-oxygen-species-and-activation-of-intrinsic-mitochondrial-pathway-in-h1299-lung-cancer-cells
#20
Jong-Woon Shin, Sae-Bom Kwon, Yesol Bak, Sang-Ku Lee, Do-Young Yoon
The compound (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) is known as an inhibitor of dual specific phosphatase 1/6 and mitogen-activated protein kinase. However, its precise anti-lung cancer mechanism remains unknown. In this study, the effects of BCI on the viability of non-small cell lung cancer cell lines NCI-H1299, A549, and NCI-H460 were evaluated. We confirmed that BCI significantly inhibited the viability of p53(-) NCI-H1299 cells as compared to NCI-H460 and A549 cells, which express wild-type p53...
March 28, 2018: Science China. Life Sciences
keyword
keyword
23402
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"